Skip to Main Content

Paper Details

Real-world outcomes using PD-1 antibodies and BRAF +⿿MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
J Eur Acad Dermatol Venereol
10
2023
BRAF, MEK, NIV, PD-1 antibodies, PEM, anti PD-1, dabrafenib, irAEs, melanoma, patients, pembrolizumab, skin cancer, stage III-IV, trametinib
Author NameAffiliation
Reinhard DummerDermatology Clinic, University Hospital Zurich and University of Zurich
Reinhard DummerDermatology Clinic, University Hospital Zurich and University of Zurich
  • 1 - 2

Datasets

Release 1.2